Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$IVDN Feature: $1 Million Milestone & Continued Profitability Projected for First Half of 2025 with Accelerating Sales for Key Supplier in Multi-Billion Homebuilding Industry: Innovative Designs, Inc. (Symbol: IVDN)
By: Get News
April 07, 2025
https://markets.financialcontent.com/streetinsider/article/getnews-2025-4-7-1-million-milestone-and-continued-profitability-projected-for-first-half-of-2025-with-accelerating-sales-for-key-supplier-in-multi-billion-homebuilding-industry-innovative-designs-inc-symbol-ivdn/
From the article:
$IVDN New Board Member for Superior Insulation Maker has Ties to Industry Leaders Including D.R. Horton $DHI, Ryan Homes $NVR and More / Super Small Share Structure with Only 38 Million OS / 16 Million Float
Sole Maker of Patented Insultex® Insulation Delivering Construction Cost and Energy Saving Performance Superior to All Competition.
Unique Evacuated Cell House Wrap Material Provides an Unmatched R-6 Rating, Water Vapor, Air & Wind Barrier and Other Important Advantages.
Over $1 Million in Revenue with Profitability Projected in the First Half of 2025.
Fiscal First Quarter Results Deliver Over a 720% Increase, Largest Percentage Revenue Growth in Company History.
Profitability Reached for First Time at Fiscal 2024 Year-End on Almost 300% Revenue Increase vs. Previous Year.
New Government Building Codes Require Continuous Insulation with Higher Performance. IVDN Meets or Exceeds These Standards Where Many Competitors Now Do Not.
Increased Order Fulfilment Capabilities with Plans for Further Enhancement to Handle Strongly Increasing Demand.
Process Underway for Uplisting to OTCQB Tier.
New Board Member is Experienced Real Estate Developer with Relations to Top Homebuilding Names Including D.R. Horton, NVR / Ryan Homes and More.
$CYCU: Cycurion CEO Kevin Kelly Provides Corporate Update in Letter to Stockholders
MCLEAN, Va., March 18, 2025 (GLOBE NEWSWIRE) -- Cycurion (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, provides a corporate update in a Letter to Stockholders from CEO Kevin Kelly:
Dear Fellow Stockholders,
After a volatile first month of trading following Cycurion’s entrance into the Nasdaq market, I want to reiterate the Cycurion team’s and my commitment to our stockholders. We remain highly confident in achieving our objectives that will ultimately drive intrinsic enterprise value growth underpinned by three key levers:
Expansion of our groundbreaking AI-powered ARx Security Platform, which we believe has the potential to revolutionize the cybersecurity market and serve as a game-changer for Cycurion with its high SaaS margin profile.
Organic companywide growth, including expanding current client relationships where there is tremendous opportunity for growth, primarily in the ARx vertical, driven by a focused strategy that includes sales & marketing talent additions.
Opportunistic and accretive acquisition strategy that seeks complementary additions to Cycurion’s existing offerings, while expanding sales reach. This strategy offers selling enterprise/government cybersecurity and IT support firms a value realization opportunity with a growing, trustworthy successor.
ARx Security Platform – Significant Organic, High-Margin AI-Powered Cybersecurity Growth Platform. At the heart of our growth strategy is the recently announced ARx Security Platform, an unrivaled cybersecurity innovation with the potential to disrupt the existing cybersecurity landscape. Powered by advanced AI technology, this robust solution provides real-time insights and protection against evolving cybersecurity threats. ARx offers a comprehensive multi-layered defense mechanism that includes a Web Application Firewall, Bot Mitigation, and Geo Gating. Additionally, as a pure SaaS offering, ARx can be deployed in a rapid and seamless manner without cumbersome and costly network hardware installations.
With high product margins, the ARx Security Platform is both a cybersecurity industry breakthrough and the foundational future contributor to Cycurion’s growth. We are laser-focused on expanding this high-margin & ROI segment to drive sustained growth and establish a formidable position in the cybersecurity space. We strongly believe ARx’s value proposition will ultimately be positively reflected in the price of Cycurion stock upon the market both obtaining a better understanding of the offering’s worth and making the connection for all stakeholders that Cycurion is now a leading cybersecurity provider. We look forward to sharing more details on our vision for ARx and its growth over the coming months.
Our Team. Cycurion’s success has always been built on the expertise and dedication of our world-class team of cybersecurity professionals. We have 70 great employees, many possessing the highest level of government security clearance, working at the upper echelon of government and corporate organizations, ensuring superior client service and driving our growth.
Accretive Acquisitions for Enhanced Capabilities. Cycurion will also seek growth with an opportunistic lens via highly strategic, complementary acquisitions that are designed to enhance our capabilities and extend our reach in both the government and commercial sectors. These prospective acquisitions will be designed to strengthen our technology portfolio, expand our client base, and accelerate our growth. By complementing our cutting-edge ARx Platform with these prospective strategic additions, we intend to reinforce Cycurion’s leadership in cybersecurity innovation and ensure Cycurion is well-equipped to meet the demands of a rapidly changing market.
Capital Structure Update
Current outstanding number of shares of common stock is just over 30 million, which yields a basic market capitalization of $16.2 million, based on the closing share price on March 17 of $0.54; and
If all the of outstanding shares of the various series of preferred stock are converted and all of the outstanding warrants are exercised for shares of common stock, the pro forma total number of shares of then-outstanding common stock would be approximately 46 million (excludes the pre-existing SPAC warrants that are significantly out-of-the-money, exercisable at $11.50/share); and
The total potential capital that Cycurion could receive from the exercise of all of the warrants that remain outstanding (excluding the $11.50 SPAC warrants) would be approximately $4.0 million.
Conclusion. We believe we have a highly valuable solution in our ARx Security Platform. We are enthusiastic about executing our growth strategies as we strive to deliver lasting value to our stockholders. We are confident in accomplishing the task at hand and will seek to buttress our stance by adding talented individuals who are aligned with our core beliefs and driven to succeed. We believe that Cycurion is optimally positioned to capitalize on the rapidly growing global demand for cybersecurity solutions with cybercrime costs projected to reach $10.5 trillion annually, and the cybersecurity market nearing $200 billion.
Moreover, we are mindful of the heightened volatility in the price of Cycurion’s stock over the recent weeks. The challenging broader market, and the technology sector in particular, has been under significant pressure since the middle of February, coincidentally when we completed the transaction that brought Cycurion public. That said, please rest assured that all of us, Alvin McCoy (CFO), the Board of Directors, the entire integrated Cycurion team, and I are working with the singular mission to execute our model and drive increasing value for Cycurion stockholders. We thank you for your initial support, and we look forward to sharing additional positive news with you in the near future.
Sincerely,
Kevin Kelly
Cycurion CEO
About Cycurion
Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies, Cloudburst Security, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients with a commitment to securing the digital future.
Forward looking Statements
This letter to our stockholders and press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion’s business.
Many factors could cause Cycurion’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such factors could include, among others, those detailed in its Registration Statement on Form S-4, as filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in that filing with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and Cycurion does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. Cycurion cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Investor Contact:
CORE IR
investors@cycurion.com
Media Contact:
Phone: (703) 555-0123
Email: media@cycurion.com
https://www.globenewswire.com/newsroom/ti?nf=OTM5NjExOSM2ODEwOTYwIzIyOTg5MDA=
https://ml.globenewswire.com/media/ZDYzMDIwNzgtNzkyZC00ZDIzLTgxMzktZjdkOTFmNDE2N2M2LTEzMTA0NTAtMjAyNS0wMy0xOC1lbg==/tiny/Cycurion.png Source: Cycurion
$IVDN (16 Million Float): Innovative Designs, Inc. Reaches Profitability for First Time by Reporting of Record Sales Results in Fiscal Year 2024, Delivering Almost 300% Revenue Increase vs. Previous Year
Sales of Superior Evacuated Cell Home Insulation Continue to Surge Into the Fiscal First Quarter for 2025
PITTSBURGH, PA - March 3, 2025 (NEWMEDIAWIRE) - Innovative Designs, Inc. (OTC Pink: IVDN) is extremely pleased to report that the Company has now achieved the key milestone of reaching profitability on the record setting revenue results of its 2024 fiscal year. With the filing of our 10K Annual Statement for the fiscal year ending on October 31, 2024 just posted, IVDN has reported that sales revenues increased to $1,382,733 vs. $347,763 for the 2023 fiscal year. This rapid growth translates to a 298% increase in sales, mostly attributable to the rising demand for our unmatched Evacuated (Vacuum) Cell R-6 Insultex House Wrap.
Fiscal fourth quarter sales were even stronger than we anticipated when we issued our projection in December for a year-end total at $1.2 million. Robust sales are currently continuing in the first half of fiscal 2025. We are working on the largest backorder level for Insultex House Wrap® that the Company has ever experienced and making progress with our suppliers to accelerate product production rates.
Sales of Insultex House Wrap® are now benefiting from new government building codes calling for continuous insulation and exterior R-Value requirements. Insultex House Wrap® is starting to be recognized as the very best option to satisfy the new requirements in terms of performance, cost effectiveness and ease of installation. Insultex House Wrap delivers its advantages thanks to its patented vacuum cell structure design. No other product on the market today offers a vacuum cell structure. A vacuum is the best thermal insulation possible and only Insultex® incorporates countless evacuated cells. Insultex® also provides a moisture barrier and other key benefits. The result is a substantial savings for new construction, adding an R-6 moisture barrier membrane that does not need additional insulation boards or other support as with other available choices from competitors.
Joseph A. Riccelli Jr., the new CEO of Innovative Designs, stated, "We have entered a new and much more rewarding stage of our business as demonstrated by the unprecedented sales results reported in our fiscal 2024 year-end financial report that has just been filed. Reaching the turning point of becoming a profitable company is a great achievement that everyone on our team has worked hard at for many years. With the growing success of the superior Insultex House Wrap® product line, Innovative Designs is positioned to continue building on the financial success we have now reached throughout 2025 and beyond. I am looking forward to arranging IVDN shareholder's conference in the near future to further expand on the reasons for our success, and plans to increase production to meet the rising demand. Additionally, we will be looking into expanding our marketing and sales options for the IDI Gear Insultex® clothing lines. Stay tuned for details on the scheduling of this upcoming IVDN shareholder's conference soon."
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit: http://www.insultexhousewrap.com and http://www.idigear.com
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph A. Riccelli Jr., CEO
412-799-0350
riccellijjr@insultexhousewrap.com
http://www.insultexhousewrap.com
$LLLI News: Lamperd Less Lethal Issues Letter to Shareholders on Prospects for Substantial Business Growth in 2025 in the Marketing of Advanced Security Products
Source: https://www.otcmarkets.com/filing/html?id=18269579&guid=RhB-kpwMD3RSJth
SARNIA, ON / March 10, 2025/ Lamperd Less Lethal, Inc. (OTC PINK:LLLI), an innovation leader and manufacturer of advanced security solutions for law enforcement, military and security agencies worldwide, today issued the following letter to shareholders from Company Chairman and CEO Barry Lamperd.
Dear LLLI Shareholders:
Over the past many months our team has been carefully laying the groundwork to lead the Company to a significantly higher revenue return from the marketing of our well proven line of less lethal weapons, munitions, riot shields and other vital security products. The new prospects come from international relationships we have built in multiple countries around the world including The USA, Mexico and Middle East countries where the demands for new and better security solutions have been growing dramatically. Additionally, the present situation with US President Trump imposing substantial tariffs and the resulting counter tariffs, is creating an environment where Lamperd products from Canada are now much more desirable to users within Canada and also in certain other countries like Mexico.
In the Middle East, Lamperd’s Chief Information Officer and International Marketing Representative, Amer Ebied has completed a number of successful trips to key countries including Jordan, UAE and Saudi Arabia. Mr. Ebied has held extensive talks and made presentations with some of the top ranking members of these countries’ governments, law enforcement and military. An important aspect of these efforts was the setting up of local assembly points for Lamperd products so that we can more easily and quickly deliver samples and full orders in the region without having to wait extended periods to obtain export permits in Canada. The feedback from the client prospects we have received has been especially positive on this point.
Mr. Ebied reports that his contacts are all very impressed with the Lamperd product line which reflects decades of intensive research and development work, in conjunction with our University associates, to be the safest and the most effective in the industry today. We are now very optimistic that new orders in the Middle East will begin within the first half of 2025 and that the revenue growth from these new prospects for Lamperd Less Lethal will be far beyond anything we have seen in the Company’s history.
Also, Lamperd has been working closely with our newly signed distributor based in Mexico, Intersec, Inc. Founded in 1974, Intersec is dedicated to meeting the needs of the Defense, Public and Private Security market in North America, Latin America and worldwide. In 2024 Intersec made important connections and presentations for specific Lamperd products which were very favorably received by representatives of the Mexican military establishment. We are now in a good position to reap the benefits of these efforts within the 2025 budget year for orders to commence on Lamperd products to Mexican agencies, processed through our authorized representative, Intersec.
Lamperd has additionally signed a Master Distributor agreement with NAPC Defense, Inc. (OTC Pink: BLIS). This agreement is for sales and distribution of the full Lamperd product line and training services to law enforcement, military and other government authorized agencies in the USA and other countries around the world where NAPC Defense has established customer relations.
NAPC Defense is licensed and approved to broker munitions and military hardware already produced and in inventory at various locations worldwide. NAPC Defense benefits from the ability to bid and win contracts that are set aside in the Defense industry from a vast knowledge of government contracting. Recently NAPC Defense has been presenting Lamperd products at important events including the annual SHOT Show in Las Vegas, NV as well as Police Chief’s Conventions in Jacksonville, FL and Atlantic City, NJ.
Years of intense and cooperative research have been devoted to developing and testing Lamperd Less Lethal munitions products. Now we feel the sleeping giant is ready to bring back a key product that was first introduced in 2017 for the drone market. The purpose is to directly engage and bring down unwanted drones in the air by prop entanglement. Police services that have 40mm launchers are ready to address this increasingly important application and Lamperd inventory will be available for them to buy into this incredible product. Also for the increasingly important anti-drone role, Lamperd is now working on a joint-venture project to develop a launchable electronic interference munition which would disrupt flying drones without direct contact just by entering their flight area and bring them down more intact for retrieval and examination.
In summation, all of us on the Lamperd team, including our administrative, marketing, manufacturing and training personnel, have been working hard to develop new avenues of revenue growth for the Company. We are confident that in this year of 2025, when the need for safe and effective security solutions has never been greater, Lamperd products will begin selling and going to work on the largest scale of our Company’s history as a result of the multiple new and larger marketing avenues we have been putting into place. We look forward to providing more updates on specific contracts and orders in the balance of this year as they are booked.
Sincerely, Barry Lamperd, Chairman and CEO
About Lamperd Less Lethal:
Lamperd Less Lethal, Inc. is a developer, manufacturer and international sales company for advanced less lethal weapons, ammunition and other security products marketed to police, correctional, military and private security forces. The company manufactures and sells over 300 different products including small & large caliber projectile guns, flash-bang devices, pepper spray devices, 12 Gauge, 37mm & 40mm launching systems and a variety of different riot shields. Lamperd also offers advisory services and hands-on training classes run by highly accredited instructors. For more information on Lamperd Less Lethal, Inc. visit: http://www.lamperdlesslethal.com
This press release contains forward-looking statements relating to Lamperd Less Lethal, Inc.
Lamperd Less Lethal, Inc. undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact: Lamperd Less Lethal, Inc.
Barry Lamperd, President & CEO
(519) 344-4445
Email: info@lamperdlesslethal.com or sales@lamperdlesslethal.com
Company Website: http://www.lamperdlesslethal.com
Lamperd Less Lethal on Facebook: https://www.facebook.com/lamperdlesslethal
Lamperd Less Lethal on Twitter: https://www.twitter.com/LLLI_
LessLethal Barry Lamperd on Twitter: https://www.twitter.com/lamperd_llli
$CYCU and $IQST: Cycurion (NASDAQ: CYCU) and iQSTEL Form Exclusive Cybersecurity Partnership to Expand into High-Tech, High-Margin Markets
MCLEAN, Va., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU), a publicly traded leader in next-generation cybersecurity solutions, is excited to announce an exclusive partnership with iQSTEL Inc. (OTCQX: IQST), a multinational innovator in telecommunications, fintech, electric vehicles (EV), and AI-driven solutions. This strategic collaboration grants Cycurion exclusive rights to deliver its top-tier cybersecurity products to the U.S. telecommunications industry through iQSTEL’s vast network while also expanding its reach into other high-growth sectors internationally.
With iQSTEL’s extensive global presence—spanning 17 time zones and seven offices worldwide—this partnership will drive the adoption of advanced cybersecurity solutions across Europe, Latin America, the Middle East, and the United States. By integrating Cycurion’s cutting-edge security expertise with iQSTEL’s established client base, both companies are poised to unlock new high-margin opportunities in the rapidly evolving cybersecurity landscape.
A Transformational Milestone for Cycurion
This partnership marks a significant expansion for Cycurion as it extends its world-class cybersecurity offerings into the global telecommunications industry and beyond. Having built a reputation for excellence among U.S. government agencies, including FEMA, TSA, and the U.S. Courts, Cycurion (NASDAQ: CYCU) is now leveraging iQSTEL’s strong business platform to introduce its advanced security solutions to a wider audience.
Kevin Kelly, Chairman and CEO of Cycurion, stated:
“Our partnership with iQSTEL represents a pivotal moment in Cycurion’s growth. By combining our unparalleled cybersecurity expertise with iQSTEL’s trusted relationships and operational strength, we are delivering next-generation security solutions to telecom providers and other industries worldwide. This is more than just a business move—it’s a strategic initiative to protect critical infrastructure, enhance customer confidence, and drive substantial growth for both companies.”
By addressing the most pressing cybersecurity challenges—including increasing regulatory compliance demands, a global shortage of security professionals, and the rising frequency of cyberattacks—Cycurion and iQSTEL are positioned to transform these industry pain points into major business opportunities.
A Next-Generation Cybersecurity Strategy
Cycurion’s comprehensive portfolio of cybersecurity services includes:
24/7 security monitoring and real-time threat detection
Rapid incident response and crisis management
Advanced vulnerability assessments and risk mitigation
Regulatory compliance solutions to meet evolving industry standards
Trusted by government agencies and now expanding into private-sector telecommunications and technology markets, Cycurion’s expertise will enable iQSTEL’s clients to fortify their security postures while maintaining seamless operations.
Leandro Iglesias, CEO of iQSTEL, commented:
“At iQSTEL, we’ve spent years building a trusted business platform for our clients, and this partnership with Cycurion adds another powerful dimension to our high-tech, high-margin offerings. Cybersecurity is no longer optional—it’s a fundamental necessity for our clients. By bringing Cycurion’s state-of-the-art solutions into our ecosystem, we are not only enhancing security but also creating new revenue streams and strengthening our leadership in high-growth markets.”
Key Benefits for Clients and Investors
This partnership delivers a host of advantages for both customers and investors, including:
24/7/365 Advanced Threat Protection – Continuous monitoring and rapid response to cyber threats.
Enhanced Customer Confidence & Revenue Growth – Robust security measures to prevent data breaches that could undermine trust and financial stability.
Regulatory Compliance & Data Privacy – Ensuring businesses meet stringent security requirements while protecting sensitive data.
Financial & Competitive Advantage – iQSTEL’s scale allows for cost-effective implementation of high-quality cybersecurity solutions.
Expansion into High-Growth Markets – The collaboration reinforces both companies’ positions in fintech, EV, AI, and telecommunications security.
A Shared Vision for the Future
This strategic alliance exemplifies how Cycurion and iQSTEL are shaping the future of cybersecurity and telecommunications. With iQSTEL’s established client network and Cycurion’s best-in-class security solutions, both companies are well-positioned to capitalize on the increasing global demand for advanced cybersecurity.
Investors are encouraged to take note: with iQSTEL forecasting $290 million in revenue for FY-2024 and Cycurion (NASDAQ: CYCU) emerging as a publicly traded leader in cybersecurity, this partnership marks a key milestone in the growth trajectories of both companies.
About Cycurion, INC. (NASDAQ: CYCU)
Headquartered in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a premier publicly traded cybersecurity provider specializing in multi-layered defense systems, continuous monitoring, and incident response. The company is trusted by U.S. government agencies, including FEMA, TSA, and the U.S. Courts, and is now expanding into private-sector telecommunications and technology markets through its partnership with iQSTEL.
About iQSTEL (OTCQX: IQST)
iQSTEL Inc. (OTCQX: IQST) (www.iQSTEL.com) is a multinational telecommunications, fintech, electric vehicle, and AI company in the final stages of uplisting to NASDAQ. With a projected $290 million in revenue for FY-2024 and a long-term goal of reaching $1 billion by 2027, iQSTEL is expanding rapidly through high-tech, high-margin product offerings. Its divisions include:
Telecommunications Services (VoIP, SMS, Fiber-Optic, IoT, Blockchain)
Fintech (Remittance, Debit Cards, Mobile Banking)
Electric Vehicles (EV) (Motorcycles and Mid-Speed Cars)
AI Services (AI-driven Metaverse platform)
Cybersecurity (Now powered by Cycurion)
iQSTEL has completed 11 acquisitions since 2018 and continues to grow through strategic M&A and organic expansion.
Safe Harbor Statement
This news release contains forward-looking statements based on current expectations and assumptions. Actual results may vary due to risks and uncertainties. This press release does not constitute an offer of securities for sale.
This partnership marks a defining moment for both Cycurion (NASDAQ: CYCU) and iQSTEL (OTCQX: IQST)—ushering in a new era of high-tech, high-margin growth in cybersecurity and beyond.
Email- Info@cycurion.com
Phone: 888-341-6680
$ONAR News: ONAR's Storia Fuels sbe's Disruptive Restaurant Group's Online Growth, Accelerating the Global Hospitality Titan's Dominance
LOS ANGELES, March 4, 2025 /PRNewswire/ -- ONAR (OTCQB:ONAR) is thrilled to announce their flagship marketing agency, Storia selected by sbe's Disruptive Restaurant Group to elevate its digital presence, is deploying its proprietary artificial intelligence and digital marketing tactics to showcase the brand's signature hospitality experiences and drive growth across its diverse portfolio of properties.
Disruptive Restaurant Group (DRG), a global hospitality group renowned for its innovative and stylish dining concepts led by restaurant visionary Founder & CEO Sam Nazarian, will harness the creative power of Storia, an agency known for imaginative and ground-breaking performance marketing campaigns. Through a combination of paid digital advertising and search engine optimization, Storia will help DRG:
Increase brand visibility: Enhance brand awareness and reach a wider audience through targeted advertising campaigns.
Drive online traffic: Attract potential customers to DRG's websites and social media channels.
Generate more leads and reservations: Convert online traffic into tangible business results.
Improve local SEO: Optimize local search rankings to attract nearby customers.
While the services that Storia is offering DRG are customized to their unique needs, Storia's offerings are founded upon a potent mix of performance strategy, agile AI-enhanced creativity, and cutting-edge data science.
"We are excited to partner with sbe's Disruptive Restaurant Group," said Heather Cardillo, Vice President at Storia. "Our talented team is ready to amplify DRG's exceptional dining experiences by delivering tech-driven digital marketing solutions. We're eager to unlock their full business potential with innovative paid advertising and SEO solutions."
This strategic alliance underscores the ONAR network's commitment to providing high-octane digital solutions to world-class clients and further solidifies ONAR's position as a dominant force in the marketing industry.
ONAR CEO, Claude Zdanow, also expressed enthusiasm about this new opportunity. "This new partnership is a testament to Storia's exceptional capabilities and our commitment to providing specialized marketing agencies to middle market clients," said Zdanow. "By leveraging Storia's expertise in performance advertising and SEO, we're confident in our ability to elevate DRG's online presence and drive significant growth."
About Storia
Storia is a brand amplification agency that combines the unceasing creativity of a design studio with the strategic ingenuity of performance marketing into a one-stop shop. This gives their team the opportunity to craft, sharpen & hone transformative brand narratives that deliver measurable business results.
About sbe
Established in 2002 by Founder and CEO Sam Nazarian, sbe is a privately-held, leading lifestyle hospitality company that develops, manages and operates world-class hotels, restaurants, lounges and nightclubs. Through exclusive partnerships with cultural visionaries, sbe is devoted to creating extraordinary experiences throughout its proprietary brands with a commitment to authenticity, sophistication, mastery and innovation. Over the last decade, sbe has mastered the art of creating desirable destinations; the lifestyle platform included over 100 hotels and 150 restaurants and lounges. In 2020, Sam Nazarian shifted his focus to the culinary and nightlife world by launching Disruptive Restaurant Group (DRG.) DRG incubates and operates globally renowned culinary brands including critically-acclaimed restaurants, lounges and nightclubs. By partnering with an impressive roster of internationally renowned culinary talent, DRG concepts are committed to innovation and setting new industry standards. Restaurants and lounges include: Casa Dani, by three Michelin-starred Chef Dani Garcia; Citizens; Katsuya, by Chef Katsuya Uechi; Kumi; MXO by Wes Avila, Doheny Room; HYDE; LiFE; and S Bar. In 2023, sbe announced its foray back into hotels with PROJECT HQ Hotels & Residences, a smart lifestyle concept launched via a strategic alliance with Wyndham Hotels & Resorts. In 2024, sbe announced The Estate, set to be the biggest network of resorts and residential projects driven by a commitment to functional and preventive medicine through diagnostics, longevity, all powered by AI. Sam Nazarian has consistently demonstrated his ability to anticipate and shape the future of hospitality and gastronomy. With his unwavering passion, entrepreneurial prowess, and a portfolio of iconic brands, Sam has cemented his position as a trailblazer in both the hospitality and culinary world for generations to come. To learn more, visit sbe.com.
About ONAR
ONAR (OTCQB: ONAR) a leading marketing technology company and marketing agency network, now publicly traded as Onar Holding Corporation. ONAR's mission is to provide unparalleled service through an integrated, AI-driven approach, leveraging its diverse brand family's strengths. Committed to honor, candor, and best-in-class results, ONAR aims to lead the industry by example, ensuring every client relationship is deeply rooted in trust and excellence.
ONAR has nearly 50 employees across five continents, and it is aggressively expanding its team to support the company's growth and acquisition pipeline. Its agencies service over 45 clients across various industries:
Performance Marketing & SEO: Our high-touch performance marketing agency, Storia, specializes in brand growth, data-driven excellence, and paid advertising.
Full-Service Healthcare Marketing: Partnering with healthcare professionals, Of Kos provides the best possible patient experience and strives to revolutionize the standard of care.
Experiential Marketing & Events: CHALK is an experiential marketing powerhouse of event architects who turn bold ideas into unforgettable reality, designing events that dare to defy the ordinary.
Pioneering Technology Incubator: ONAR Labs is a team of data scientists, engineers, and industry experts who are identifying, developing, and commercializing innovative marketing technology solutions born from servicing our agency clients, battle-tested by our network to ensure real-world applicability and impact.
ONAR's network of agencies focuses on servicing companies ranging from $50M to $1B+ in revenue, and ONAR is actively searching for agencies to acquire and become part of the network.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on ONAR's current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy, and financial needs. These statements are not historical facts and are inherently uncertain and outside of ONAR's control. Forward-looking statements include, among other things, statements regarding ONAR's expectations regarding its ability to achieve its financial and strategic goals, including surpassing $100 million in revenue and securing a NASDAQ listing; its ability to expand its client base and market share; and its ability to develop and launch new products and services. Actual results may differ materially from ONAR's expectations and projections due to various risks and uncertainties, including market conditions, competition, the ability to protect intellectual property, the ability to manage growth, changes in laws and regulations, and other factors described in ONAR's filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and ONAR undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/onars-storia-fuels-sbes-disruptive-restaurant-groups-online-growth-accelerating-the-global-hospitality-titans-dominance-302391077.html
$IQST - iQSTEL Releases 2025 Shareholder Letter Highlighting Strategic Growth, M&A 2025 Campaign, and Vision for a $1 Billion Corporation Future
NEW YORK, Jan. 21, 2025 /PRNewswire/ -- iQSTEL Inc. (OTCQX: IQST), a leading innovator in the technology and telecommunications sectors, is pleased to share its 2025 Shareholder Letter, outlining the company's strategic initiatives, financial performance, and bold vision for the future. Below is the full letter from CEO Leandro Iglesias:
iQSTEL logo (PRNewsfoto/iQSTEL)
Letter to Shareholders
Dear Valued Shareholders,
As we embark on 2025 with great enthusiasm and a bold vision for the future, I am thrilled to share iQSTEL's strategic direction, remarkable achievements, and ambitious goals. Your unwavering trust and confidence inspire us to push boundaries and achieve extraordinary milestones. Together, we are building a company destined for greatness, driven by innovation, profitability, and an unrelenting focus on delivering exceptional shareholder value.
Extraordinary Know-How in M&A
iQSTEL has established itself as an expert in identifying, acquiring, and integrating high-value companies. Over the course of 11 successful venture and acquisitions, we have refined a strategic approach that consistently drives growth and strengthens our position as a leader in the technology and telecommunications industries.
Our most recent acquisition, QXTEL, exemplifies this expertise. From April to December 2024, QXTEL generated $85 million in net revenue and $950,000 in EBITDA, based on preliminary accounting. These results highlight iQSTEL's ability to identify and unlock value, setting the stage for our ambitious M&A campaign in 2025.
A Bold Step Forward: Our M&A 2025 Campaign
This year, iQSTEL is launching an ambitious Mergers and Acquisitions (M&A) campaign designed to accelerate our growth trajectory. Our goal is to acquire a company within the Telecom, Fintech, Cybersecurity, or AI services sectors, generating tens of millions of dollars in revenue and contributing over $1 million EBITDA annually.
We intend to complete this acquisition before reaching NASDAQ, where even greater opportunities await us. To support this campaign and advance our broader business objectives, we have just filed an S-1 registration, reflecting our commitment to securing the resources necessary for transformative growth.
Enhancing Shareholder Value Through Strategic M&A and Organic Growth
At iQSTEL, we place our shareholders at the core of our strategic decisions. Our carefully planned M&A initiatives, combined with robust organic growth, have driven substantial increases in Revenue Per Share (RPS) over recent years:
2020: $0.380
2021: $0.439
2022: $0.577
2023: $0.839
2024 (preliminary accounting): $1.364
This impressive RPS growth trajectory reflects the success of our strategy to create sustainable shareholder value. By pursuing high-margin opportunities through both M&A and organic initiatives, we anticipate maintaining this rapid growth pace.
Our strategy safeguards shareholder value, ensuring that market perceptions align with the underlying strength demonstrated by our growing RPS and improving profitability. This positions iQSTEL as a leader in its industry and strengthens our foundation for sustained success.
Building on Our Momentum in 2025
2024 was a pivotal year for iQSTEL. We achieved critical mass, with our operating businesses generating positive net income quarter after quarter. This success underscores the strength of our strategy and our ability to execute effectively. For 2025, we aim even higher:
Revenue Forecast: $340 million
EBITDA Forecast for our operating business: $3 million
These milestones are more than just numbers—they are a testament to the dedication of our team, the support of our shareholders, and our relentless pursuit of growth. They represent a critical step toward achieving our vision of becoming a $1 billion revenue company with eight-digit positive EBITDA by 2027.
Even More, Continuous Progress and Innovation in 2025
Every day, iQSTEL takes bold steps to strengthen its business and ensure a brighter future:
Rebranding: We are positioning iQSTEL as a technology leader, delivering high-margin, high-tech products to our customers. We have introduced our new logo and plan to share more results from our rebranding collaboration with ONAR.
Cost Reduction and Efficiency: We are implementing strategies to streamline operations, accelerate EBITDA growth, and enhance shareholder value. In the coming days, we will announce further cost-reduction initiatives to bolster profitability.
Cybersecurity Product Launch: Thanks to our strategic partnership with Cycurion, we are set to launch our cybersecurity products this quarter and begin sales in the first half of 2025. This initiative expands our portfolio to address critical global needs.
AI Services Growth: Our AI platform, Airweb.ai, continues to gain customers and partners, underscoring its transformative potential. New AI services will launch in the first half of 2025, reinforcing iQSTEL's reputation as a powerhouse of innovation.
NASDAQ Uplisting: Building a Strong Foundation
Our journey toward a NASDAQ uplisting is progressing steadily and strategically. While we are not rushing, we have been giving time for organic growth to enhance our stock price, supported by the strength of our operating business, forecasted to generate $3 million in EBITDA in 2025.
If the management decided that is the right time to jump into Nasdaq, and we have not achieved yet the organic price will be when the management will decide to expedite the uplisting process through a reverse stock split, at that time we will ensure full transparency by filing an SEC notice. Any reverse stock split, if executed, will be aligned with and in conjunction with the NASDAQ uplisting.
We are committed to building a company that captures the attention of national investors and reflects the immense value we offer.
Management's Commitment: Aligned with Shareholder Interests
At iQSTEL, our leadership team is not just steering the company toward its ambitious goals; we are also deeply invested in its success. As the largest shareholder group, management holds the equivalent of 40.5 million common shares through a combination of common and preferred shares. This significant ownership reflects our unwavering belief in iQSTEL's potential and aligns our interests directly with those of our valued shareholders.
This commitment is a testament to the confidence we have in iQSTEL's vision of becoming a $1 billion revenue corporation by 2027. Our substantial stake in the company ensures that management is fully aligned with long-term value creation. Every strategic decision we make—whether it involves organic growth initiatives, high-margin product expansion, or strategic acquisitions—is driven by a shared goal: to deliver sustainable growth and maximize shareholder value.
The road to achieving our $1 billion revenue milestone is clear, and our investment in iQSTEL underscores our dedication to seeing it through. We are not merely stewards of the company; we are also shareholders, invested in its future and committed to building a prosperous and sustainable enterprise for years to come.
Confidence of Long-Term Investors: Extending Support for a $1 Billion Vision
Our vision of achieving $1 billion in revenue by 2027 is not just a statement—it is a well-defined plan that has garnered the trust and support of long-term investors. Their confidence in our strategic direction is evidenced by their willingness to extend the maturity dates of convertible notes originally used to acquire QXTel in 2024.
These notes, previously set to mature in 2025, now have extended maturity dates through 2026, providing iQSTEL with additional financial flexibility to execute our growth strategy. This extension underscores the belief that we are on a clear trajectory to achieve our ambitious goals and deliver exceptional returns.
Our long-term investors recognize the importance of supporting iQSTEL as we transition to a Nasdaq listing and continue to build momentum towards our revenue and profitability targets. Their ongoing commitment reflects their trust in our ability to execute our plans and deliver on our promises.
A Brilliant Future Ahead
iQSTEL is more than a company—it's a testament to the power of vision, hard work, and innovation. Together, we are creating something extraordinary, a company that delivers exceptional financial results while driving meaningful progress across industries.
This is an incredibly exciting time for iQSTEL. The journey we are on is transformative, and the opportunities ahead are limitless. Thank you for being part of this journey, for believing in our vision, and for sharing in our success. Together, we will achieve extraordinary milestones and secure a bright and prosperous future for iQSTEL and its shareholders.
Warm regards,
Leandro Iglesias
President & CEO, iQSTEL Inc.
About iQSTEL:
iQSTEL Inc. (OTC-QX: IQST) (www.iQSTEL.com) is a US-based multinational publicly listed company in the final stages of the path to becoming listed on NASDAQ. With FY2024 revenues of $277 million based on preliminary accounting, iQSTEL is positioning itself for explosive growth. iQSTEL's mission is to serve basic human needs in today's modern world by making essential tools accessible, regardless of race, ethnicity, religion, socioeconomic status, or identity. The company recognizes that modern human needs such as physiological, safety, relationship, esteem, and self-actualization are marginalized without access to ubiquitous communications, financial freedom, clean, affordable mobility, and information.
iQSTEL has been building a strong business platform with its customers, and by leveraging this trust, the company is now beginning to sell high-tech, high-margin products across its divisions. iQSTEL is strategically positioned to achieve $1 billion in revenue by 2027 through organic growth, acquisitions, and high-margin product expansion.
Telecommunications Services Division (Communications):
Includes VoIP, SMS, International Fiber-Optic, Proprietary Internet of Things (IoT), and a Proprietary Mobile Portability Blockchain Platform.
Fintech Division (Financial Freedom):
Provides remittance services, top-up services, a MasterCard Debit Card, US bank accounts (no SSN required), and a Mobile App.
Electric Vehicles (EV) Division (Mobility):
Offers Electric Motorcycles and plans to launch a Mid-Speed Car.
Artificial Intelligence (AI) Services Division (Information and Content):
Provides AI solutions for unified customer engagement across web and phone channels, along with a white-label platform offering seamless access to services, entertainment, and support in a virtual 3D interface.
Cybersecurity Services:
Through a new partnership with Cycurion, iQSTEL will offer advanced cybersecurity solutions, including 24/7 monitoring, threat detection, incident response, vulnerability assessments, and compliance management, providing essential protection to telecommunications clients and beyond.
iQSTEL has completed 11 acquisitions since June 2018 and continues to develop an active pipeline of potential future acquisitions, further expanding its suite of products and services both organically and through mergers and acquisitions.
Safe Harbor Statement: Statements in this news release may be "forward-looking statements". Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and iQSTEL Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/iqst---iqstel-releases-2025-shareholder-letter-highlighting-strategic-growth-ma-2025-campaign-and-vision-for-a-1-billion-corporation-future-302355880.html
SOURCE iQSTEL
$ACGX News: Alliance Creative Group ($ACGX) Reports Sale of Chicago Property with Financial Gains; New Investments Now Being Sought
February 10, 2025
News Link:
https://www.einpresswire.com/article/784083279/alliance-creative-group-acgx-reports-sale-of-chicago-property-with-financial-gains-new-investments-now-being-sought
$ACGX is pleased to announce the Company’s real estate property located at 6403 N. Wayne Ave Chicago, IL has been successfully sold for $3,450,000.
CHICAGO, IL, UNITED STATES, February 10, 2025 /EINPresswire.com/ -- Alliance Creative Group, Inc., (ACGX.us) (Stock Symbol OTC: ACGX) is pleased to announce the Company’s real estate property located at 6403 N. Wayne Ave & 1324 W. Devon Ave, Chicago, IL has been successfully sold for $3,450,000. This sale now represents a reduction of $3,311,552 in Liabilities from the 9/30/24 Balance Sheet along with $264,243 in cash deposited in the ACGX bank account.
ACGX is now searching to find additional investment opportunities with the net cash proceeds and improved balance sheet from the Chicago property sale to help increase our overall shareholder value. Ideally, we are seeking to acquire majority control of a positive cashflow subscription software or services business to help scale and grow. Our target objective is for an acquisition in the $1 million to $5 million revenue range that has potential for exponential growth.
Our full financial statements, balance sheets, statement of operations, cash flow statement, and disclosure statements are posted on the OTC Market Company website at www.OTCmarkets.com under the stock symbol ACGX in the section for filings and disclosure and on www.ACGX.us in the investor relations section.
Paul Sorkin, CEO of the Alliance Creative Group, Inc. said, "We are excited to have completed the sale of our Chicago real estate property. With the multiple benefits that this sale has delivered to ACGX we are now in a very favorable position to progress on to our next investment opportunities. We are currently reviewing some options but we certainly welcome all assistance from any parties in identifying new investments that would meet our criteria, particularly in the software or services business.”
The Company’s shares of www.PeopleVine.com continue to be a very rewarding investment for ACGX and the conversations with the growth capital investment groups have been quite beneficial. Our goal is to convert between 20% to 30% of the PeopleVine investment into cash in 2025 so we can use a lot of it to invest in future projects while we let the majority of the shares hopefully continue to increase in value.
About Alliance Creative Group, Inc.
Alliance Creative Group, Inc. (Stock Symbol: ACGX) is a Parent Holding Company on the OTC market. The strategy ACG intends to deploy is a shared resource model where internal divisions, portfolio companies, Real Estate projects, and strategic investments are vertically integrated, optimizing efficiencies and cost savings. Resources may be applied to a mix of early-stage equity investments in companies that synergize with the company's shared resource model and secured investment opportunities. ACG's strategic mission is to utilize a unique blend of capital, relationships, experience, and secured investment structures to increase value for its clients, partners, investors, and shareholders while reducing the overall risk. The company's big picture long term plan is to create an ecosystem of shared resources that can provide quality resources with reduced expenses while acting as a partner for internal projects. The intent is to have multiple businesses and investment projects or divisions to help diversify the risk and generate potential revenue in multiple ways while leveraging both the private and public markets. For more information, visit www.AllianceCreativeGroup.com or http://www.ACGX.us.
About PeopleVine
PeopleVine is a Software as a Service (SAAS) company that specializes in serving the Lifestyle Hospitality industry. The Member Experience & CRM Software allows luxury hotels, resorts, and private member clubs to elevate a more personalized online membership experience. PeopleVine helps their clients build member communities, drive engagement, and connect the dots that elevate experiences and revenues. The software empowers its clients teams to deliver efficiently managed operations through an integrated platform. PeopleVine is committed to being the most essential and adaptive SaaS engagement platform for companies that take a customer centric approach to business.
For more information http://www.PeopleVine.com
This news release contains forward-looking statements as defined by the bespeaks-caution doctrine. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Relations and Media Contact
info@ACGemail.com
SOURCE Alliance Creative Group, Inc.
Paul Sorkin
Alliance Creative Group, Inc.
paul@acgemail.com
$IQST: iQSTEL's Bold Vision: $1 Billion in Revenue by 2027 Shareholder Update
$ACGX consistently shows us strong and growing financial results which are reported on time each quarter. This is the definition of a value stock that is serving its investor base well.
From the latest ACGX news:
Revenues for the Quarter ending September 30, 2024 ("Q3 2024") were $102,990 Gross Profits for the Quarter ending September 30, 2024 ("Q3 2024") were $102,990 Net Income for the Quarter ending September 30, 2024 ("Q3 2024") were ($44,912)
The total assets on the Balance Sheet for the Alliance Creative Group as of 9/30/24 were $4,543,643
The total outstanding common shares as of September 30, 2024 were 4,454,211 with 2,799,023 of those shares in the float - Same as the end of the last quarter, and since March.
The Company ended the quarter with $88,220 Cash on hand.
$GPOX: GPOPlus+ Shareholder Update & Highlights which include 560% Year over Year revenue growth, Reporting $4.35 million annual revenue, and Deploying proprietary AI-powered technology platform PRISIM+ - Predictive Route Inventory + Service Management!
Click here:
https://finance.yahoo.com/news/gpoplus-shareholder-130000903.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$BLIS (NAPC Defense) has issued 4 extremely positive announcements recently. These include a signed LOI on a $370 Million defense contract in the Middle East (See Oct. 22nd news below).
Oct. 29, 2024: NAPC Defense and Lamperd Less Lethal form Partnership for Security Products Marketing in The USA and Worldwide
https://www.morningstar.com/news/globe-newswire/9263212/napc-defense-and-lamperd-less-lethal-form-partnership-for-security-products-marketing-in-the-usa-and-worldwide
Oct. 25, 2024: NAPC Defense (OTCPK: BLIS) to Demonstrate Corner Shot and Attend SWAT Round-Up 2024 as a Convention Exhibitor
The Company Plans to Meet with leading SWAT Team Members, Law Enforcement Officers, Military Personnel, and other Industry Experts
https://www.globenewswire.com/en/news-release/2024/10/25/2969429/0/en/NAPC-Defense-OTCPK-BLIS-to-Demonstrate-Corner-Shot-and-Attend-SWAT-Round-Up-2024-as-a-Convention-Exhibitor.html
Oct. 24, 2024: NAPC Defense (OTCPK: BLIS) Awarded in Excess of $1 Million in Clean-up Contracts following Hurricanes Helene and Milton
The Company is Working on Additional Potential Restoration and Clean-up Contracts
https://finance.yahoo.com/news/napc-defense-otcpk-blis-awarded-120500313.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
Oct. 22, 2024: NAPC Defense, Inc. (OTCPK: BLIS) issues Progress Report regarding Large Contract with Saudi Arabia
https://www.globenewswire.com/news-release/2024/10/22/2966948/0/en/NAPC-Defense-Inc-OTCPK-BLIS-issues-Progress-Report-regarding-Large-Contract-with-Saudi-Arabia.html
$RENB News: RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024.
This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) derived from blood plasma to detect key copy number alterations (CNAs) in lung cancer patients. CNAs are a key hallmark of cancer and can be used in cancer monitoring, prognosis prediction, targeted therapy, and precise cancer subtyping.
“The research demonstrates that Oxford Nanopore sequencing of cell-free DNA from blood plasma can effectively capture significant copy number alterations (CNAs), which characterize the copy number landscape of lung cancer tissues—traditionally assessed through tissue biopsy,” said Khashayar Roohollahi, senior scientist at RenovaroCube.
Furthermore, CNAs can be used to estimate tumor fractions which is useful for predicting cancer progression and monitoring. The study emphasizes the potential of this technology in reducing the need for invasive tissue biopsies, a significant advancement in oncology.
Read more about the poster: https://renovarogroup.com/novel-insights-on-non-invasive-cancer-diagnostics-poster/
RenovaroCube remains committed to advancing precision medicine through innovative research and technologies, offering hope for more effective, patient-centered cancer care.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments utilizing non-invasive liquid biobsy. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.
About MAP
MAP focuses on current and emerging approaches in precision oncology, highlights successes and challenges, and proposes potential solutions in clinical research and practice.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com and STarsh@Renovarogroup.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTI1Nzg5NiM2NTM3ODEwIzIxMjA2Nzk=
https://ml.globenewswire.com/media/N2ExZjNkNDktODBhZC00MGRlLWE4OWItNjY5MWQ1ODYwOWNiLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
$RENB News: Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
AMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube’s advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which RenovaroCube is based.
Prof. Mark Hoogendoorn, also a professor of Artificial Intelligence, expressed his enthusiasm: “We were pleased to be engaged to make an assessment of the AI platform; this is exactly the area of PersonalAIze’s expertise.”
Frank van Asch remarked on the collaboration, “The expertise of PersonalAIze’s team is exceptional, and their positive evaluation of our AI/ML platform is invaluable.”
RenovaroCube's AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.
The initial aim is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.
In their analysis, PersonalAIze noted the platform's focus on liquid biopsies and third-generation sequencing coupled with AI techniques as highly promising, potentially allowing for comprehensive analysis across varying cancer types and stages. Prof. Sandjai Bhulai, also a professor of Mathematics, commented on the platform’s unique potential and the impressive multidisciplinary team at RenovaroCube under Frank van Asch’s leadership.
Based on these findings, PersonalAIze is eager to collaborate further with RenovaroCube to enhance and commercialize the platform.
PersonalAIze aims to contribute in several key areas:
Advancing AI models by leveraging the latest state-of-the-art techniques.
Supporting the professional growth of the software team.
Enhancing the explainability of AI models, engaging clinicians in model development.
Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.
This partnership could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.
About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
About PersonalAIze
PersonalAIze focusses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision making systems as well as improvement of health care operations such as capacity planning.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTIzMTk2NCM2NDgyMzM1IzIxMjA2Nzk=
https://ml.globenewswire.com/media/ZGJkNzBkMGQtY2Y5ZC00OTJkLWFkNTYtMjAwZmFjZWQzZmQzLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
"How NRx Could Upend the Fight Against Depression and Suicide"
RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit http://www.nrxpharma.com.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL03022&sd=2024-09-11 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
MIAMI, Sept. 3, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company") and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a presenting companies at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9-11, 2024.
The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.
Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx and Co-CEO of Hope, will provide an overview of the Company's business during the presentation.
If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference.
Event: H.C. Wainwright 26th Annual Global Investment Conference
Date: September 9-11, 2024
Location: Virtual to start on-demand on September 9 at 7:00 A.M. (ET) or in-person at the Lotte New York Palace Hotel, New York, NY.
Access to the presentation can also be found at https://ir.nrxpharma.com/events beginning at 7:00AM ET Monday September 9, 2024.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About H.C. Wainwright & Co.
H.C. Wainwright is a full–service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.
For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL96063&sd=2024-09-03 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-announce-participation-at-the-hc-wainwright-26th-annual-global-investment-conference-september-9-11-2024-302236168.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP News: HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
$30 million Term Sheet from qualified lender for non-dilutive financing for first clinic acquisitions; anticipated closing within 60 days
Executed Non-Binding Term Sheet with initial clinic partners generating annual revenue of over $10 million, with additional partners to be selected under this initial funding agreement
Company projects annualized revenues of $100 million through continued acquisition by mid 2025
Additional information to be presented at upcoming HC Wainwright Annual Global Investment Conference in New York, September 9-11, 2024
MIAMI, Aug. 26, 2024 /PRNewswire/ -- HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("HOPE," the "Company"), a medical and technology driven company, today announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, the Company has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. The Company anticipates potential operations in the United States, France, and the United Kingdom.
The non-dilutive acquisition funding announced today is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange.
Ketamine is increasingly used to treat suicidal depression, treatment resistant depression (TRD) and Post Traumatic Stress Disorder (PTSD). Until now there has been no unified entity organized around delivering consistent outpatient care for suicidal depression, TRD and PTSD that combines pharmaceutical therapy, FDA approved and proven medical technologies such as Transcranial Magnetic Stimulation (TMS), digital therapeutics and access to clinical trial protocols for the newest potential treatments, delivered by properly licensed medical professionals to optimize care of people with these conditions. Collectively, these conditions represent a crisis that results in the death of someone around the globe every minute. HOPE aims to bring a unified, patient-centric and science-based approach to the care of patients and their families.
"HOPE is dedicated to providing an accessible platform to help caregivers address the critical needs of those suffering from suicidal thoughts, TRD, PTSD and related challenges. We are delighted to take the critical first steps towards developing a network of clinics that can provide the highest possible level of care and demonstrate best-practices for mental health professionals around the world," said Jonathan Javitt and Matthew Duffy, Co-CEOs of HOPE Therapeutics. "These clinics, and others under review, are planned to provide the foundation for a network generating revenue of approximately $100 million annually in the coming year."
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-potential-acquisition-and-financing-agreements-for-30-million-in-currently-operating-interventional-psychiatry-clinics-302230157.html
SOURCE NRx Pharmaceuticals, Inc.
$IDVV News: Winners Waygers AI Powered Sports Handicapping Assistant Launched In Beta
Carlsbad, California--(Newsfile Corp. - August 15, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced that its WITech.ai division launched a one of a kind artificial intelligence (AI) powered sports handicapping assistant today.
We are pleased to announce the launch of winnerswaygers.com in a free beta mode today thus expanding our AI's ability into sports handicapping. IEC's WITech division plans to expand the service quickly into a subscription based model featuring all major sports using the popularity of the NFL football and fantasy betting season as a catalyst to make users aware of the service.
The AI is currently used by professional handicappers that helped to develop the tools and datasets for the AI. WITech is transforming the current complex model into a user friendly service that will appeal to all.
Current plans are to launch in phases starting with a beta mode offering users the ability to sign up for the service for free. Upon the start of the NFL season in September 2024 users will begin receiving handicapping information from the AI to assist in their decision making.
Our goal after beta is to launch our paid subscription service featuring an interactive sports handicapping bot in Mid October 2024 along with an expansion into Hockey and Basketball. We will be offering a discount to any users of the beta version who wish to upgrade at that time.
We are planning in Q4 of 2024 to begin charging $77 per league selected, for example NFL, and will offer an all sports league package for $247 per year/season. As previously indicated there will be a discount for beta members. At that time the beta version will become a free weekly newsletter featuring one pick to allow potential paid subscribers to see how the service works. We have been seeing massive interest in this service and feel we will have thousands of subscribers as the paid service gets rolled out.
Winners Waygers spokesperson Marrion Lewis stated, "We are excited offer the service to the mainstream. For far too long only professionals have had access to the complex data used to make more accurate sports bets. We plan to change the game. The NFL is the most popular sport to bet, so it is fitting to use it for our launch. I'm personally rooting for the chiefs, but we'll let the AI decide."
IDVV board member Ray Valdez stated, "This is the first expansion of the company into adult related, and more importantly recession resilient sectors. With the potential of many thousands of subscribers we are looking forward to discussing winners waygers along with other opportunities the company is pursuing shortly."
Winners Waygers Video
https://vimeo.com/999064151?share=copy
Relevant Links
https://www.americangaming.org/resources/economic-impact-of-legalized-sports-betting/
https://www.statista.com/topics/10895/fantasy-sports-in-the-us/#topicOverview
https://www.espn.com/nfl/story/_/id/39469575/americans-expected-bet-231b-super-bowl-lviii
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com.
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone:833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/220044_9ae4a1780431c9ef_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220044
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/220044/130
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update
Company is now funded for and focused on New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics is now complete, SEC filing of spinout this quarter
Key Milestones
Secured $10.8 - $16.3 million in convertible-debt funding from an institutional investor; funds targeted to support FDA New Drug Applications for NRX-100 (ketamine) and NRX-101. Replacement funding entails substantial reduction in interest rate, conversion discount, and other financial terms compared to prior debt
Retirement of Streeterville debt and settlement of litigation at a substantial discount to litigation claims
NRX-100 NDA for suicidal depression based on data from four clinical trials in nearly 1000 participants demonstrating highly significant efficacy compared to placebo, active comparator, and electroshock therapy
Ketamine findings have just been confirmed in published 43,000 person cohort study1
Phase 2b/3 trial of NRX-101 in suicidal patients with bipolar depression demonstrated depression efficacy comparable to standard of care and significant reduction of akathisia (P=0.025) and time to sustained remission from suicidality (P=.05). Presented at the annual meeting of the American Society of Clinical Psychopharmacology. Profile demonstrates possible best in class bipolar depression medication
Company plans to file a New Drug Application (NDA) for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101 in treatment of bipolar depression in people akathisia or suicidality, based on the Phase 2b/3 and STABIL-B data
Stability data continues to mature on the three manufacturing lots required for the NRX-100 (IV ketamine) NDA filing and the Company announced alignment with FDA on its Pediatric Study Plan for NRX-100, also a requirement for filing an NDA
HOPE Therapeutics, the Company's wholly owned subsidiary, is focused on developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders. HOPE is planned to be spun out as a separate company to be owned by NRx, current NRx shareholders, and new investors. This effort will be funded apart from NRx.
Appointed Dr. Dennis McBride, a Neuroscience, Information Technology and Medical Technology Veteran, to its Board of Directors
Management to host a conference call August 14, 2024, at 4:30 PM ET
RADNOR, Pa., Aug. 14, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year to date ended June 30, 2024, and provided a business update.
"NRx has continued to execute on our plans to file two NDA's this year. As we near maturation of NRX-100 stability data, we also achieved an important milestone in aligning with FDA on our pediatric study plan. Together with strong clinical data from four clinical trials, we believe this application will be quite robust. Additionally, the important data generated from two trials conducted by NRx with NRX-101 in suicidal bipolar depression sets the stage for a second NDA for Accelerated Approval later this year. Finally, work continues to spin out Hope Therapeutics and distribute shares to NRx stockholders. We believe reaching these important milestones will generate significant value in the company and reward our shareholders," said Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx Pharmaceuticals. "Facilitated by funding to allow us to achieve these goals and while replacing the prior expensive and toxic debt on our balance sheet, we are in a position to deliver therapy that can meet considerable unmet medical need in millions of patients across the country. We are dedicated to bringing hope to life and I thank our team and shareholders for their ongoing hard work and support."
Second Quarter Clinical, Regulatory and Corporate Highlights
Funding for FDA filings of NRX-100 and NRX-101
The Company has executed a Convertible Debt instrument with Anson Funds of Toronto for $10.8 - $16.3 million in funding designed to retire existing debt and to support FDA New Drug filings of NRX-100 and NRX-101 in the fourth quarter of 2024. Terms have been disclosed in 8K filings but are at an interest rate and conversion rate substantially lower than current corporate indebtedness. The new funding has no provision for "extraordinary redemptions" triggered by appreciation in NRx share price.
Retirement of current debt and settlement of litigation
Concurrent with the Anson investment, the Company has settled its outstanding litigation with Streeterville Capital, LLC at a substantial discount to the amounts claimed in litigation.
Progress towards an NDA for NRX-100 (IV ketamine) in the treatment of suicidal depression
Intravenous ketamine has now become a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product. Intranasal Esketamine is approved by the FDA (SPRAVATO®) but has not demonstrated a benefit on suicidality and is not approved for use in patients with bipolar depression. Attempts to use intranasal racemic ketamine for suicidal depression have failed.
The Company has formed data-sharing partnerships to license clinical trial data from a French Government-funded trial and two NIH-funded trials all of which demonstrate efficacy of racemic Intravenous ketamine against depression and two of which demonstrate statistically significant benefit vs suicidality. The Company's role is to reformat these data into the required presentation required for review by the FDA.
In contrast to nasal ketamine, Intravenous racemic ketamine demonstrates dramatic and immediate reduction of suicidality in patients with both Major Depressive Disorder and Bipolar Depression. Grunebaum and colleagues demonstrated a rapid and statistically significant reduction in Suicidal Ideation (SSI) at day 1 (p=0.0003) and in depression (P=0.0234), as measured by the Profile of Mood States (POMS) among patients randomized to IV Ketamine compared to those randomized to midazolam. This trial was published in the American Journal of Psychiatry Grunebaum, et.al.2. Abbar and colleagues similarly published 84% remission from suicidality on the Columbia Suicide Severity Rating Scale (C-SSRS) in patients treated with ketamine, vs. 28% in those treated with placebo (P<.0001). This trial was published in the British Medical Journal3. Data are expected to be transmitted to FDA by in 2024.
In November 2023, the Company initiated manufacture of ketamine together with Nephron Pharmaceuticals, Inc. (West Columbia, SC) to develop a single patient presentation of ketamine. Nine months of real-time stability is ongoing, the minimum stability time required for a New Drug Application. This presentation of ketamine does not contain the preservative included in multi-dose vials, (Benzanthonium Chloride), that is designed to preserve sterility in the vial when multiple doses are drawn for multiple patients. The Company is not aware of any data to support the safety of this preservative for repeated IV administration. Data were collected 20 years ago that demonstrated the toxic effect of this class of preservatives when applied repeatedly to the surface of the eye, which led to the current generation of preservative-free eye drops. NRX-100 will therefore be launched as a preservative-free presentation.
A long-term challenge with ketamine is that the current formulation (KETALAR®) is highly acidic. While it is suitable for intravenous use, it cannot be administered subcutaneously. In March 2024 the Company demonstrated the formulation of a pH neutral patentable form of IV ketamine that it anticipates will have widespread applicability both in treatment of depression and chronic pain.
Development of NRX-101 for Suicidal Treatment-Resistant Suicidal Bipolar Depression
The Company presented final data from the recently completed phase 2b/3 trial of NRX-101 in suicidal bipolar depression4 at the American Society of Clinical Psychopharmacology's annual meeting. These data demonstrated a significantly improved safety profile versus the standard of care, as demonstrated by a clinically significant reduction in akathisia (P=0.025) and time to sustained remission from suicidality (P=0.05). Akathisia is an adverse event seen with antidepressant medications considered by many experts to be a precursor to suicide. Given the vital need for safer medications in this at-risk population, we plan to submit an NDA for Accelerated Approval to the US FDA for treatment of bipolar depression patients with suicidality or akathisia, based on these data as well as additional data from our STABIL-B5 trial.
Incorporation of HOPE Therapeutics
In February we first presented the contours of HOPE Therapeutics, a subsidiary that will focus on the delivery of advance psychiatric treatments, including ketamine-focused treatment for depression and suicidality. Unlike the core business of NRx Pharmaceuticals, that is focused on biotechnology Research and Development, HOPE is organized around consolidating existing best-in-class clinics into a nationwide network. This has been done previously and without much success with clinics that are not necessarily psychiatrist-led. As currently designed, the HOPE consolidation is likely to be funded as a separate entity, through bond offerings and, thus, to be non-dilutive to NRx shareholders. Over the past quarter, HOPE leadership has identified the clinics that are most likely to participate in the first $100 million consolidation, has completed the audit required for a public listing of HOPE shares, and has identified appropriate underwriters for a future bond offering.
With Hope ownership as an asset of NRx, this will further strengthen the NRx balance sheet and aims to further enhance NRx shareholder value.
NRX-101 for Treatment of Chronic Pain:
In 2023, the Company licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain. Data lock has now been achieved in a 200-person randomized prospective trial funded by the US DOD (NCT 03535688) in which patients with chronic pain were randomly assigned to DCS 400mg/day vs. placebo. Should these results support efficacy of DCS in the treatment of chronic low back pain, they are expected to provide a Breakthrough Therapy path towards treatment of chronic pain with DCS and DCS-containing medicines.
Treatment of Urinary Tract Infection (UTI) and Urosepsis:
Although treatment of UTI is quite different from use of NRX-101 to treat Central Nervous System disorders, D-cycloserine was originally developed as an antibiotic because of its role in disrupting the cell wall of certain pathogens. During Q3 2023, NRx tested NRX-101 and its components against resistant pathogens that appear on the Congressionally mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRx was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA in January 2024.
In recent years, increased antibiotic resistance to common pathogens that cause urinary tract infections and urosepsis (i.e., sepsis originating in the urinary tract) has resulted in a marked increase in cUTI, hospitalization, and death from urosepsis. The US Center for Disease Control and Prevention reports that more than 1.7 million Americans contract sepsis each year, of whom at least 350,000 die during their hospitalization or are discharged to hospice (CDC Sepsis Ref.)6. There are approximately 3 million patients per year who contract cUTI in the US annually (Lodise, et. al.)7. Additionally, should NRX-101 succeed in clinical trials, the Company will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
A key challenge in the treatment of cUTI is the tendency of advanced antibiotics to cause C. difficile infection, which is fatal in 10% of those who contract it over the age of 65 and results in prolonged hospitalization in many more. The Company recently announced data demonstrating that NRX-101 does not compromise the intestinal microbiome, unlike common antibiotics including Clindamycin and Ciprofloxacin. Should these findings be documented in human patients, NRX-101 would represent the only treatment for cUTI that does not cause C. Difficile infection.
In The Company does not anticipate funding this initiative with core NRx assets and is exploring structures for partnership opportunities. Should the Company or its partners succeed in serving 10% of the cUTI market, the Company believes that the revenue from NRX-101 has the potential to be hundreds of million annually, based on 3 million cases per year in the US and potential pricing of over $3,500/course of therapy.
Financial Results for the Quarter and Year to Date 2024
For the three months ended June 30, 2024, we at NRx Pharmaceuticals reduced our net loss from $8.7 million in the second quarter of 2023 to $7.9 million in 2024, representing nearly a 10% improvement year over year. For that same period, we reduced research and development expenses from $3.9 million in 2023 to $2.8 million in 2024. The $1.1 million decrease is related primarily to a decrease of $2.4 million in clinical trial and development expenses, offset by an increase of $1.3m related to the Alvogen warrants. Also in that 3 month period we recorded an increase in general and administrative expenses, from $4.1 million in 2023 to $4.2 million in 2024. The increase of $0.1 million is related primarily to an increase in consultants and legal fees partially offset by lower insurance expenses.
For the six months ended June 30, 2024, NRx Pharmaceuticals reduced its net loss to $14.4 million compared to $19.8 million in the prior year. These efficiencies represent an improvement in net loss of $5.4 million year over and a $1.32, or 47%, improvement in net loss per share year over year. Over that six-month period we recorded $4.6 million of research and development expenses compared to $7.5 million for the same period in 2023 representing a 39% decrease year over year. The decrease of $2.9 million is related primarily to a decrease of $4.1 million in clinical trial and development expenses, $0.3 million related to fees paid to regulatory and process development consultants while offset by $1.3 million related to the Alvogen warrants and $0.4 million related to fees paid to regulatory and development consultants. Also in that six-month period, we decreased G&A by $1.4 million, from $9.9 million in 2023 to $8.5 million in 2024, nearly a 15% decrease year over year.
As of June 30, 2024, we had $1.9 million in cash and cash equivalents. As previously stated, we recently announced we secured up to $16.3 Million Senior Secured Debt Financing from Anson Funds. This financing is expected to support 2024 filing of New Drug Applications for NRX-100 (ketamine) and NRX-101 and to support launch of HOPE Therapeutics as well as retire historical debt with more favorable terms, and a lower annual interest rate.
NRx continues to implement operational efficiencies to extend cash runway and maintain focus on our path to generating revenue and value for our shareholders.
Please see detailed financials on our Form 10-Q, filed with the SEC and available on our website.
Conference Call and Webcast Details
A live webcast of the conference call will be available on the Company's website at 4:30 p.m. ET today, at https://ir.nrxpharma.com/events. An archive of the webcast will be available on the Company's website for 30 days. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally 1-646-307-1865.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (http://www.hopetherapeutics.com) is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
1 Pan, Y., Gorenflo, M.P., Davis, P.B. et al. Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study. Transl Psychiatry 14, 327 (2024). https://doi.org/10.1038/s41398-024-03033-4
2 Grunebaum, et. al., Ketamine for Rapid Reduction of Suicidal Thoughts. Am J Psychiatry. 2018 Apr 1: 175(4): 327-335
3 Abbar, et. al. Ketamine for Acute Treatment of Severe Suicidal Ideation, BMJ 2022; 376
4 Nierenberg, et. al., A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/ lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior. Am Soc Clin Psych Annual Meeting 2024.
5 Nierenberg et al. International Journal of Bipolar Disorders (2023) 11:28 https://doi.org/10.1186/s40345-023-00
6 https://www.cdc.gov/sepsis/what-is-sepsis.html
7 Open Forum Infectious Diseases, Volume 9, Issue 7, July 2022, ofac315, https://doi.org/10.1093/ofid/ofac315
https://c212.net/c/img/favicon.png?sn=CL84005&sd=2024-08-14 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-reports-second-quarter-and-year-to-date-2024-financial-results-and-provides-business-update-302222664.html
SOURCE NRx Pharmaceuticals, Inc.
$CATV On The Brink Of Major Biotech Acquisition
https://www.degenmag.com/post/catv-on-the-brink?fbclid=IwZXh0bgNhZW0CMTEAAR3JeK6FnTkxWKrJ_DGdNQIetrmaeLVZWu95CgJQbUnn4-kVcxLqS6KRYKk_aem_4HuKAP7r6qqO5vYOWbQGtA
$GRLF: Green Leaf Innovations, Inc. Sets Sail for History
Join Cubanacan Heritage at Battleship New Jersey Museum's Annual 'Cigars on the River' Event
PEMBROKE PINES, FL / ACCESSWIRE / May 15, 2024 / Green Leaf Innovations, Inc., (OTC PINK:GRLF), an importer and wholesale distributor of premium hand-rolled cigars, is proud to announce its participation in the highly anticipated 'Cigars on the River' event at the iconic Battleship New Jersey Museum and Memorial.
Overlooking the majestic Delaware River and the breathtaking Philadelphia skyline, this annual soirée promises an unforgettable evening of indulgence and philanthropy. Guests will savor the finest cigars, exquisite cuisine, and handcrafted cocktails amidst the historic setting of the Battleship New Jersey.
Cubanacan Heritage, a cornerstone of Green Leaf Innovations, Inc.'s esteemed portfolio, will take center stage at this prestigious event, showcasing the rich heritage and unrivaled craftsmanship behind each meticulously hand-rolled cigar.
About Battleship New Jersey Museum and Memorial: The Battleship New Jersey Museum and Memorial stands as a testament to our nation's military prowess and enduring legacy. From its storied past in World War II to its pivotal role in modern naval history, the battleship offers a captivating glimpse into the triumphs and sacrifices of our armed forces. Immerse yourself in a journey through time and honor the heroes who have served our country with courage and valor.
Don't miss this exclusive opportunity to join Green Leaf Innovations, Inc. and Cubanacan Heritage aboard the Battleship New Jersey for an evening of camaraderie, celebration, and support for a noble cause.
About Green Leaf Innovations, Inc.
Green Leaf Innovations, Inc., a Florida corporation, is an emerging growth company engaged in the Marketing and Distribution of handmade premium cigars. The company strategically imports and exclusively distributes some of the best known premium cigar brands in the Market created by the Mederos family a Third generation Cigar maker with Robert Mederos at the helm who has owned and operated handmade cigar operation in Nicaragua and the US for over 20 years with a rich family history in the craft dating back to the 1800s Cuba, brands such as CUBANACAN, MEDEROS and TABACALERA SERRANO. In addition to it the company also distributes packaged whole leaf Tobacco to cigar lounges, smoke shops, C-stores and vape shops across the United States and soon International Markets.
Additional information can be found on our websites http://www.greenleafinnovation.com or follow us on Twitter @otcgrlf.
For more information, press only:
PR Contact Name: Ryan Medico
Phone number: (800) 303-6268
Email: info@greenleafinnovation.com
Safe Harbor Statement:
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. The Company may also make written or oral forward-looking statements in its filings with the U.S. Securities and Exchange Commission, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Reports on Form 10-K and its other filings with the Securities and Exchange Commission. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control. The Company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise.
SOURCE: Green Leaf Innovations, Inc.
$AVRW News: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results
New Initiatives Showing Encouraging Results
SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.
Key financial highlights for the fourth quarter included the following:
Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.
Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.
Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.
Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.
Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.
"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.
Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.
Operational Highlights
Other operational highlights during the fourth quarter of 2023 included:
Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/
About Avenir Wellness Solutions, Inc.
Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: www.avenirwellness.com.
About The Sera Labs, Inc.
Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
CONTACTS:
Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com
$AVRW @AvenirWellness Leading LA Plastic Surgeon Recommends Seratopical Skin Care for Superior Anti-Aging Performance: (Stock Symbol: AVRW) - World News Report - EIN Presswire
Cliock here:
https://world.einnews.com/article/688477296/leading-la-plastic-surgeon-recommends-seratopical-skin-care-for-superior-anti-aging-performance-stock-symbol-avrw
$RENB News: Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.
Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts of cfDNA data that is highly accurate.
"At RenovaroCube, we believe in pushing the boundaries of possibility," states Daan Vessies, senior scientist at RenovaroCube. "Flamingo undescores our commitment to change cancer diagnostics in a transformative way, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers."
The Company believes that no single model or molecular modality will reach the requisite sensitivity and specificity throughout the entire patient journey for personalized, precision medicine, from early detection, to predicting the effectiveness of various treatment options, to monitoring the response to therapy within days of starting it, to detecting recurrence at the earliest possible moment. Therefore, our AI/machine learning platform, The Cube, integrates multi-omic data, offering a uniquely comprehensive approach to cancer detection by leveraging a library of trained models for multiple omic layers. One such model Flamingo focuses on is the detection of cancer from ultra-low pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.
Flamingo's development marks a significant milestone in the quest for early cancer detection with RenovaroCube’s engine. By utilizing as few as only 200,000 cell-free DNA fragments per sample, integrating fragment lengths, sequence motifs and employing a meticulously designed neural network, Flamingo achieves remarkable performance in distinguishing cancer from healthy samples.
By augmenting The Cube's arsenal of models operating across various omic layers, Flamingo contributes to the development of non-invasive diagnostics to detect cancer early, enabling timely interventions and improving patient outcomes.
"Adding Flamingo to our Cube will accelerate our efforts to realize a paradigm shift in cancer detection," affirms Frank van Asch, CTO, RenovaroCube. "With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process."
RenovaroCube invites interested doctors and scientists from international research institutions, clinical cancer centers and all stakeholders to join in the early research use application of our AI/machine learning platform to advance cancer diagnostics and pave the way for a healthier future.
About Renovaro:
Please see a recent interview with Avram Miller, Member of, and Advisor to, the Board of Directors, former co-founder of Intel Capital and SVP of Business Development for Intel:
https://techbullion.com/avram-miller-talks-ab...es-with-ai
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes RenovaroBio, with its advanced cell-gene immunotherapy company, and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
https://www.renovarogroup.com
https://www.renovarobio.com
https://www.renovarocube.com
About Cyclomics:
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland Venture Challenge (startup of the year) by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.
https://www.cyclomics.com/
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
$NCL News: Northann Corp.'s Benchwick Brand to Showcase SuperOak Hybrid Wood Planks Alongside Blue11 Collection at NWFA in New Orleans, April 16-18, 2024
ELK GROVE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Northann Corp. (NYSE American: NCL) today announced that its Benchwick brand will unveil its latest patented innovation, SuperOak Hybrid Wood Planks, before showcasing its award-winning Blue11 Collection, at the National Wood Flooring Association (NWFA) Expo in New Orleans, April 16-18, 2024, at the New Orleans Ernest N. Morial Convention Center - Hall F & G.
Combining the natural beauty of wood with the durability and sustainability of modern materials, SuperOak Hybrid Wood Planks represent a breakthrough in flooring technology. The product will be in stock across the U.S. starting in May, ensuring customers have access to this revolutionary flooring solution.
"We are thrilled to introduce our Benchwick SuperOak Hybrid Wood Planks, as well as showcase our award-winning Blue11 Collection, at NWFA," said Lin Li, CEO and President of Northann Corp. "SuperOak demonstrates our dedication to pushing the boundaries of flooring technology."
Attendees of NWFA are invited to visit Northann at booth number 2219 to explore the SuperOak and Blue11 Collection and learn more about Benchwick's cutting-edge flooring solutions.
For more information about Northann Corp. and its Benchwick brand, visit www.northann.com.
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit www.northann.com.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
https://www.globenewswire.com/newsroom/ti?nf=OTA4OTg3MCM2MjAyMzk1IzIyNTM4NDA=
https://ml.globenewswire.com/media/ZWViZDNhYWYtNmMzYS00OGZiLTlmNjItMGI4MTE3NDQ2MTEyLTEyNjUzOTM=/tiny/Northann-Corp-.png
Source: Northann Corp.
$NCL News: Northann Corp Announces Cross-Licensing Agreement with I4F for Digital Printing Technology
ELK GROVE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Northann Corp. (NYSE American: NCL), a leading innovator in 3D-printed home improvement solutions, is pleased to announce a strategic cross-licensing agreement with I4F, a group of companies providing patents and technologies to the flooring industry.
This agreement solidifies a collaborative effort between the two companies to enhance their respective offerings in the digital printing space. Northann Corp's commitment to innovation and quality aligns perfectly with I4F's expertise in digital printing technology, creating a synergy that promises exciting advancements in the flooring industry.
"Intellectual property should not be a barrier to technological and industry advancements; it should be a catalyst for continuous innovation for humanity and the industry as a whole," said Lin Li, CEO of Northann Corp. "Our cross-license agreement with I4F is designed to further democratize this technology and help I4F's digital printing licensees greatly reduce manufacturing costs and entry barriers. After this cross-license agreement, Northann Corp will manufacture its 3D printing ecosystem with digital printing production lines in the United States, drastically reducing production costs, and further solidifying Northann’s foothold within the industry."
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit www.northann.com.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
https://www.globenewswire.com/newsroom/ti?nf=OTA4NzE5NCM2MTk0NzA4IzIyNTM4NDA=
https://ml.globenewswire.com/media/Njk0MWU2ZDMtZGE3Yy00OWQ4LWIzZmQtZjE3NTg1ZDA3MTZiLTEyNjUzOTM=/tiny/Northann-Corp-.png
Source: Northann Corp.
$GVH -Experience Effortless E-commerce Shipping: Globavend Holdings Limited (NASDAQ:GVH) Tailored Solutions from Hong Kong to Your Doorstep in Australia & New Zealand!
Click here: https://axecapitalusa.com/gvh/
Welcome to the future of logistics with Globavend Holdings Limited (NASDAQ:GVH), where innovation meets opportunity in the bustling e-commerce landscape of Asia-Pacific. As pioneers in direct injection from Hong Kong & Southern China to Australia and New Zealand, we offer investors a gateway to a market projected to witness exponential growth. Our integrated cross-border logistics solutions ensure seamless parcel consolidation, air freight forwarding, and customs clearance, catering to the evolving needs of online businesses.
Strategic Expansion: With plans to establish ground transportation and customs clearance teams, we are poised to capture a significant market share.
Profitable Partnerships: As an IATA-accredited cargo agent with strong ties to top air freight carriers, we guarantee cost-effective solutions.
Robust Growth: Amidst a booming e-commerce market, our stable business model promises lucrative returns for investors seeking long-term opportunities.
Innovative Solutions: Our all-in-one shipping solution ensures operational efficiency and customer satisfaction, positioning us as industry leaders.
Invest in Globavend today and be part of a transformative journey reshaping the future of global logistics.
"Bar, While it's tough to pick the winning companies...." Munger says, "invert, always invert." In this case, focus instead on discarding losers. For the past couple years I've advised my kids to shun stocks making headlines. i.e. faddish junk such as faux meat/food stocks. Or EV stocks. Even if they sometimes succeed, new-tech stocks are often way too pricey and payouts can be years down the road.
I advise my kids to stay with rock-solid boring operations. That's 180 degrees opposite of how IHUBers pick stocks. Can you imagine sitting in BYND at $200 a share, and without a dividend? Doesn't anyone remember the soy-burger disasters of the past? Has any MJ stock worked out well for its investors?
Bar, While it's tough to pick the winning companies, the broader technology seems like a winner. I figure the best technologies will be acquired by larger players, as in other tech areas, so it will be 'Darwinian'.
Investment-wise, I currently only have the broad Aviation / Defense ETF (PPA), and a few stocks with aerospace exposure - Curtiss-Wright (CW) and Transdigm (TDG), but small positions (link below). Those I picked mainly based on their nice long term charts, so it was fairly easy. But these small newer companies would require a lot of research and knowledge, so then you are into 'Buffett territory' :o) Actually Buffett's purchase of Precision Castparts does have a sizable aerospace exposure. So even the 'Oracle' has ventured into aerospace, though he now believes he overpaid for that acquisition.
But probably best to avoid aerospace in general. My dad was in aerospace as an engineer, and he almost always avoided investing in the sector, and especially the airline stocks. Buffett learned that the hard way with his brief but disastrous foray into the airline sector a few years ago. While there was no way to predict the arrival of Covid, it's probably safe to say he'll go back to avoiding the sector like the plague :o)
Aerospace Sector -
https://investorshub.advfn.com/Aerospace-Sector-36968
---
What is that 60 or 70 firms that have played around with electric aircraft? Technology that's been around in various forms for ages. I see that none of the stocks are doing much. Many are falling, which is what I'd expect.
My guess is most of those "booked" "orders" are cancelable... just like many of the early EV car/truck orders. Remember Nikola? Or Lucid?
Bar, It looks like electric aircraft could be the future, at least for shorter haul flights under 500 miles. Here's one from the company Eviation (video below). I remember seeing the prototype for this in the news when they had it at the annual Paris Air Show (2019). Eviation began as an Israeli startup, and is now majority owned by the Clermont Group, a Singapore conglomerate, and they have $5 bil in orders. Improved battery technology will be the key to getting longer haul aircraft with bigger payloads -
Check out this long list of electric aircraft at various stages of development -
https://en.wikipedia.org/wiki/List_of_electric_aircraft
SRFM Surf Air Mobility already down to 0.82. EV flight company.
https://finance.yahoo.com/quote/SRFM?.tsrc=fin-srch
Surf Air Mobility shares slump 75% in NYSE debut
"July 27 2023 (Reuters) - Electric aviation and regional air travel company Surf Air Mobility (SRFM.N), opens new tab shares slumped 75% below their reference price in a direct listing on Thursday.
Shares debuted on the New York Stock Exchange at $5 per share below its reference price of $20.
https://www.reuters.com/markets/deals/surf-air-mobility-shares-slump-75-nyse-debut-2023-07-27/
Another cute "gadget stock." I hope it's not too much like the Osprey. LOLOL
I'll leave the gadgets for Shark Tank. Cool video, utterly devoid of facts.
Wow an aircraft produced by a penny stock! Several major aircraft companies such as Boeing are working on EVTOLs. Insuring one of those will be nearly impossible. Heck, insurance is a fortune for small recreational aircraft now.
who are the major backers of Archer Aviation
https://gemini.google.com/app/5246cc6ab7bd998d
how far along is Archer Aviation in receiving governmental approval for it eVTOL aircraft
and
who are the major backers of joby
https://gemini.google.com/app/3d6906518078942b
Ombow, It looks like JOBY has completed Phase 3 of the 5 part certification process -
>>> Joby Completes Third Stage of FAA Certification Process
https://finance.yahoo.com/news/joby-completes-third-stage-faa-130000733.html
<<<
JOBY has a mega cool technology, but I wonder about the economic viability of their air taxi business model since it only carries 4 passengers. They're going to have to charge a lot for that businessmen's flight to the airport, one would think. Another potential target market would be as a play toy for rich guys. That works great for high end cars like Ferrari, but for JOBY the rich guys would also need to have a pilot's license, and that would be a very small number of customers. Even if they make the aircraft 'autonomous' so you don't actually need a pilot's license, the cost is going to be very high, so a very limited market, one would think. The military is reportedly looking at the JOBY, but what they need is something big to replace the Osprey, and that's already in the works (Bell V-280 Valor).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174005617
So while super cool, I figure these air taxis might remain a relatively small niche product. Just a guess though.
Btw, check out these crazy guys. Looks like fun, but..
JOBY
https://www.theguardian.com/us-news/2024/mar/29/flying-taxi-joby-aviation-ohio
have joby's eVTOL aircraft received governmental approval
https://gemini.google.com/app/1ad9d490aa27d3e0
Bar, Yes, that's a great sector. I figure if it's Buffett's favorite sector, that's the place to be, and this is confirmed by their phenomenal long term charts. Here are the one's I own (below), albeit small positions. Buffett has had a bunch of these, though over the past year has reduced or eliminated some of his positions. But I'll just keep them long term since the charts are so nice. I'd like to add Allstate, but am waiting for a pullback. A lot of these are currently overbought, but I'll continue to hold them LT, as you have done for decades :o)
Insurance -
***************
SDPR Insurance ETF (KIE) (0.35%) ------------------------------------------------------------------- 1.9%
Cbiz Inc (CBZ) - Financial, insurance, advisory services (3 Bil) --------------------------------- 0%
Everest Group (EG) - Reinsurance (16 Bil) (Bermuda) ------------------------------------------ 1.9%
Globe Life (GL) - Life insurance (12 Bil) (Berkshire) ---------------------------------------------- 0.7%
Old Republic Intl (ORI) - Diversified insurance (8 Bil) -------------------------------------------- 3.4%
Primerica (PRI) - Life insurance, investment products, other (9 Bil) --------------------------- 1.2%
Insurance - Brokers -
***************************
Aon PLC (AON) - Financial services, insurance broker (60 Bil) (Ireland) (Berkshire) ---- 0.8%
Arthur J. Gallagher & Co (AJG) Insurance broker (41 Bil) --------------------------------------- 1%
Brown + Brown (BRO) - Insurance broker (17 Bil) ------------------------------------------------- 0.8%
CorVel (CRVL) - Insurance broker and diverse services (4 Bil) ---------------------------------- 0%
Marsh & McLennan (MMC) - Insurance broker, services (86 Bil) (Berkshire) -------------- 1.4%
Insurance - Property + Casualty -
*****************************************
Chubb (CB) - Insurance (97 Bil) (HQ in Switzerland) --------------------------------------------- 1.5%
Kinsale Capital Group (KNSL) - Property and casualty insurance (5.3 Bil) ----------------- 0.2%
Markel (MKL) - Insurance (20 Bil) (Berkshire) -------------------------------------------------------- 0%
Progressive Corp (PGR) - Insurance (79 Bil) -------------------------------------------------------- 0.3%
RLI Corp (RLI) - Insurance (6 Bil) ----------------------------------------------------------------------- 0.8%
Travelers (TRV) - Insurance (45 Bil) -------------------------------------------------------------------- 1.9%
WR Berkley (WRB) - Insurance (19 Bil) ---------------------------------------------------------------- 0.6%
<<<
https://investorshub.advfn.com/Financial-Sector-Ideas-25505
---
Warren Buffett’s favorite market indicator is flashing red
https://www.cnn.com/2024/03/27/investing/premarket-stocks-trading/index.html
It looks like it's just an early stage company with just one arrow in the quiver right now. Might be worth following what they do in the future.
gfp, what are your thoughts on https://invivyd.com/ ? Another PYMD or the real deal? Did you listen to Rain? If you click on the middle arrow and then on the arrow in the lower right, you'll find it - https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174100759
Bar, >> CTAS <<
That has to be the nicest long term chart of any stock, with unbelievable 'ST' (steadiness and trajectory). MMC is another one with a super nice LT chart. Owning these sure beats chasing the latest fad stock :o)
---
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2613
|
Created
|
08/18/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |